Blueshift Asset Management, LLC Argenx Se Transaction History

Blueshift Asset Management, LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$342.17 - $402.31 $88,279 - $103,795	-258 Reduced 22.05%	912 $345,000
Q3 2022 Nov 14, 2022	BUY	$343.2 - $395.75 $401,544 - $463,027	1,170 New	1,170 $413,000
Q1 2022 May 12, 2022	SELL	$254.45 - $351.06 $147,072 - $202,912	-578 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$272.01 - $353.03 $157,221 - $204,051	578 New	578 $202,000
Q3 2019 Nov 12, 2019	SELL	$113.31 - $150.51 $250,415 - $332,627	-2,210 Closed	0 $0
Q2 2019 Aug 14, 2019	BUY	$115.0 - $141.58 $254,150 - $312,891	2,210 New	2,210 $313,000

400

30.9M

376K

489K

Ticker ARGX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,323,800
Market Cap $31.2B
Description
argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...

Get notified when there are updates to the investment portfolio of Blueshift Asset Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Blueshift Asset Management, LLC with notifications on news.